{"id":9222,"date":"2024-09-23T16:45:37","date_gmt":"2024-09-23T15:45:37","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=9222"},"modified":"2024-09-23T16:48:30","modified_gmt":"2024-09-23T15:48:30","slug":"ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/","title":{"rendered":"AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<\/p>\n<h3 class=\"Default\">23\/09\/2024 \u2013\u00a0AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques (SEP), suite \u00e0 la conf\u00e9rence 2024 du Comit\u00e9 Europ\u00e9en pour le Traitement et la Recherche sur la Scl\u00e9rose en Plaques (ECTRIMS)<\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<\/p>\n<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNC8wOS9DUC1VUERBVEUtRUNUUklNUy0yMDI0Li1WRlItVkYucGRmJnNldHRpbmdzPTExMTAxMTExMTExMTExMTExMDAmbGFuZz1lbi1VUw==#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<\/p>\n<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-b13337518b6319ccd8c3ef8a8b69b77e.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-b13337518b6319ccd8c3ef8a8b69b77e > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2024\/09\/CP-UPDATE-ECTRIMS-2024.-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1727105692451\" target=\"_blank\" id=\"default-btn-b13337518b6319ccd8c3ef8a8b69b77e\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>\n<p>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 23\/09\/2024 \u2013\u00a0AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques (SEP), suite \u00e0 la conf\u00e9rence 2024 du Comit\u00e9 Europ\u00e9en pour le Traitement et la Recherche sur la Scl\u00e9rose en Plaques (ECTRIMS) [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column] [\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[134],"tags":[],"class_list":["post-9222","post","type-post","status-publish","format-standard","hentry","category-2024-fr","category-134","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science fait aujourd&#039;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science fait aujourd&#039;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-23T15:45:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T15:48:30+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024\",\"datePublished\":\"2024-09-23T15:45:37+00:00\",\"dateModified\":\"2024-09-23T15:48:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/\"},\"wordCount\":174,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2024\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/\",\"name\":\"AB Science fait aujourd'hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2024-09-23T15:45:37+00:00\",\"dateModified\":\"2024-09-23T15:48:30+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science fait aujourd'hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science fait aujourd'hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/","og_site_name":"AB Science","article_published_time":"2024-09-23T15:45:37+00:00","article_modified_time":"2024-09-23T15:48:30+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024","datePublished":"2024-09-23T15:45:37+00:00","dateModified":"2024-09-23T15:48:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/"},"wordCount":174,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2024"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/","name":"AB Science fait aujourd'hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2024-09-23T15:45:37+00:00","dateModified":"2024-09-23T15:48:30+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science fait aujourd&rsquo;hui le point sur le d\u00e9veloppement du masitinib dans les formes progressives de la scl\u00e9rose en plaques suite \u00e0 la conf\u00e9rence ECTRIMS 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/9222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=9222"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/9222\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=9222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=9222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=9222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}